Tonix Pharmaceuticals Holding Corp. (TNXP)
6.04
-0.38
(-5.92%)
USD |
NASDAQ |
Oct 16, 16:00
6.08
+0.04
(+0.66%)
After-Hours: 20:00
Tonix Pharmaceuticals Research and Development Expense (Annual) : 44.49M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 44.49M |
| December 31, 2024 | 39.97M |
| December 31, 2023 | 86.66M |
| December 31, 2022 | 81.88M |
| December 31, 2021 | 68.84M |
| December 31, 2020 | 36.16M |
| December 31, 2019 | 18.19M |
| December 31, 2018 | 17.56M |
| Date | Value |
|---|---|
| December 31, 2017 | 13.34M |
| December 31, 2016 | 30.13M |
| December 31, 2015 | 35.50M |
| December 31, 2014 | 18.62M |
| December 31, 2013 | 4.65M |
| December 31, 2012 | 2.583M |
| December 31, 2011 | 1.158M |
| December 31, 2010 | 0.5843M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Inovio Pharmaceuticals, Inc. | 52.79M |
| Nektar Therapeutics | 117.07M |
| Heron Therapeutics, Inc. | 12.43M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |